CRISPR Technology: Global Markets

Report Highlights

The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.

Report Includes

• 32 data tables and 61 additional tables
• An analysis of the global market for CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology
• Analyses of the global market trends, with data from 2021-2022, estimates for 2023, forecast for 2024, and projected CAGRs through 2029
• Discussion of the market potential for CRISPR technology
• Estimate of the market size and a revenue forecast for the global CRISPR technology market, and a corresponding market share analysis by application, end user, and region
• Discussion of the major market dynamics, regulations, industry challenges, and macroeconomic factors that will affect the demand for CRISPR technology market over the next five years
• A look at the recent breakthrough in CRISPR-Cas9 genome editing technology, and how it has propelled the rapid growth in genetic engineering and advanced pharmacological research
• A comparative study on CRISPR with TALE and ZFN nuclease as a gene editing tool and discussion on its higher adaptability over other nucleases
• Review of the patent filings and research publications for innovations in the CRISPR-Cas9 genome editing technology
• A discussion on ESG challenges and ESG practices of the industry participants
• A look at the proprietary technologies and strategic alliances of the companies best positioned in the CRISPR market
• Analysis of the industry structure, competitive landscape, clinical trials, ongoing research activities, and the impact of COVID-19
• Company profiles of the major players, including Merck KGaA, Thermo Fisher Scientific, Beam Therapeutics, CRISPR Therapeutics and Danaher Corp.

Report Scope

This report on CRISPR technology provides market projections for 2029 and analyzes the market for CRISPR technology by application and end user. Applications covered include drug development, agriculture, diagnostics and others. End users include biotechnology and pharmaceutical companies, academics and government research institutes, and contract research organizations.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Consulting Editor’s Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.